Back to Journals » OncoTargets and Therapy » Volume 7

Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Authors Hager T, Seitz B

Received 17 September 2013

Accepted for publication 7 October 2013

Published 24 December 2013 Volume 2014:7 Pages 69—77


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Tobias Hager, B Seitz

Department of Ophthalmology, Universitätsklinikum des Saarlandes, Homburg, Germany

Abstract: During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore, the pathophysiological details of their development are often poorly understood. Herein we attempt to identify groups of biologicals to which a specific side effect profile can be assigned. We also tried to capture all relevant side effects and therefore conducted several database investigation including Medline, Cochrane library, and the drugs section of the US Food and Drug Administration (FDA), using the following search strings: “name of biological agent (both generic and commercial names)” AND “eye” OR “ocular”. If we found a side effect that has been associated with a drug, we researched Medline using the following search string: “name of biological agent” (both generic and commercial names) AND “term for the specific side effect”. Due to the wealth of material we report only the drugs that are approved by the FDA.

Keywords: ocular side effect, biological, targeted therapy, interferon, EGFR

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]